Stockscreener 앱 받기
22.19
1.42%
0.31
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Structure Therapeutics (GPCR) Slides 5.23% to $33.23, Pulling Back Toward Key Support at $31.57FRAMA Signal - https://www.dars.gov.et/
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? - Zacks Investment Research
Structure Therapeutics (NasdaqGM:GPCR) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com Canada
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com India
Structure Therapeutics (GPCR) CMO sells shares under preset plan - Stock Titan
Structure Therapeutics Inc. (GPCR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com UK
Structure Therapeutics Inc.American Depositary Shares (Nasdaq:GPCR) Price Chart - The Chronicle-Journal
Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily
Structure Therapeutics at Cantor conference: oral obesity push advances By Investing.com - Investing.com Canada
Structure Therapeutics at Cantor conference: oral obesity push advances - Investing.com
Structure Therapeutics Advances ACCG-2671 with 3.3% Weight Loss; Aleniglipron Hits 16.2% Reduction (NASDAQ: GPCR) - Kalkine Media
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data - investing.com
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com UK
Structure Therapeutics (GPCR) Shares Slide After Obesity Drug Tr - GuruFocus
Jefferies raises Structure Therapeutics stock target on amylin data By Investing.com - Investing.com Canada
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Zacks Investment Research
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results - TipRanks
Oral obesity drug shows double-digit weight loss as Structure Therapeutics (NASDAQ: GPCR) advances Phase 3 trials - Stock Titan
A weight-loss pill cut body weight 16.2% in 72 weeks - Stock Titan
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
Morgan Stanley’s conference is one of three Structure Therapeutics plans to join in September - Stock Titan
Structure Therapeutics (GPCR) CSO sells 5,939 ADSs under preset plan - Stock Titan
Barinthus Biotherapeutics advances court-approved merger, Nasdaq exit - The Globe and Mail
(GPCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - Eastern Progress
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Structure (GPCR) Watch: Finishes 6.67% Down at $50.52 in the Current Update; Range Check: Support at $47.99 and Resistance at $53.05 Frame the Range at the CloseMomentum ETF - dars.gov.et
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - Eastern Progress
Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure (GPCR) Watch: Finishes 6.67% Down at $50.52 in the Current Update; Range Check: Support at $47.99 and Resistance at $53.05 Frame the Range at the CloseComposite Profile - www.dars.gov.et
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionRevenue Warning Signal - dars.gov.et
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionRevenue Guidance Update - careplusvn.com
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionNegative Surprise Momentum - dars.gov.et
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionShare Dilution Risk - dars.gov.et
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionTax Rate Impact - dars.gov.et
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock? - TradingView
Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Sell at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? - TradingView
5.80%
0.79%
자본화:
|
볼륨(24시간):